
Renal Cell Carcinoma
Latest News
Latest Videos

CME Content
More News

Sunitinib alone was noninferior for median overall survival compared with sunitinib plus cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma, according to findings from the phase III noninferiority CARMENA trial.

Arjun V. Balar, MD, Editor-in-Chief of Targeted Therapies in Oncology, discusses the plenary session at. the 2018 ASCO Annual Meeting. Findings from the CARMENA trial in metastatic clear cell renal cell carcinoma were presented.












Brian I. Rini, MD, discusses atezolizumab and bevacizumab as an effective frontline combination in RCC, as well as PROs with the regimen.

Charles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.









Although patients who develop brain metastases from renal cell carcinoma typically have poor outcomes, investigators from Yale University have identified a subset of patients who demonstrated extended survival.<sup>1</sup>Those patients with a single metastasis were less likely to develop central nervous system\ recurrence after local therapy. This is an encouraging development because these patients have historically been excluded from participating in clinical trials and receiving aggressive treatment regimens.

According to updated data from the phase I/II PIVOT-02 trial presented at the 2018 ASCO Annual Meeting, the combination of NKTR-214 plus the PD-1 inhibitor nivolumab demonstrated promising antitumor activity in patients with advanced solid tumors, particularly in PD-L1–negative patients.






































